An Overview of Therapeutic Options for Amyotrophic Lateral SclerosisMarch 4th 2023
With an anticipated life expectancy of 3 years from the time of symptom onset, an effective treatment strategy is essential in ALS—and recent therapeutic progress has built a foundation of hope for the community.
EMERGE Study Aims to Highlight Therapeutic Benefit of AXS-07 After CGRPs FailMarch 3rd 2023
Now 4 years after the approvals of the first calcitonin gene-related peptide inhibitors, new therapies are being developed to address the lingering needs of patients with refractory migraine.
Bruton Tyrosine Kinase Inhibitors: A New Hope for the Management of Progression in MS?March 2nd 2023
Several therapies are progressing through the development pipeline and have shown promising data, setting up the multiple sclerosis treatment toolbox for possible expansion in coming years.
Anti-CD20 Therapy Ublituximab Gains FDA Approval for Relapsing Multiple SclerosisDecember 28th 2022
Marketed as Briumvi, the TG Therapeutics treatment becomes the third anti-CD20 agent approved for relapsing multiple sclerosis and is expected to become available in the first quarter of 2023.
Seizure-Free Days and Duration Intervals Increased With Fenfluramine in Dravet SyndromeDecember 10th 2022
In a recent time-to-event analysis based on two clinical trials of patients with Dravet syndrome results demonstrated an overall reduction in seizure burden with fenfluramine.
NeuroVoices: Sube Banerjee, MD, MSc, MBA, FRCPsych, on Replacing Traditional Noneffective Agents for Alzheimer AgitationDecember 7th 2022
The professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the SYMBAD trial, and eliminating the use of mirtazapine and carbamazepine as medications to treat Alzheimer agitation.
Chronic ASM Use Associated With Acute Symptomatic Seizures in Patients With StrokeDecember 6th 2022
Retrospective analysis of a group of individuals with stroke suggests that nonconvulsive acute symptomatic seizures are associated with long-term use of antiseizure medications, providing key data in guiding therapy use in this population.
Cenobamate Not Associated With Clinically Significant Weight Change in Epilepsy TreatmentDecember 6th 2022
Notably, though, cenobamate treatment was associated with weight reductions among patients who were categorized as overweight and obese, but not in those who were underweight or normal weight.
XEN1101 Posts Positive Efficacy, Safety in Focal-Onset Epilepsy in Interim Phase 2b Open-Label DataDecember 5th 2022
The investigational therapy from Xenon Pharmaceuticals showed marked reductions in monthly seizure frequency from months 14 to 20, with consistent safety and good retention rates.
Transition to Adult Care Is Inconsistent for Patients With Dravet Syndrome, Survey SuggestsDecember 4th 2022
A survey conducted in conjunction with the Dravet Syndrome Foundation suggests that many patients with DS do not undergo the transition of care from pediatric to adult neurology providers, with caregivers of those who did expressing some concerns about the process.